Literature DB >> 20300921

[Meaningfullness and duration of palliative chemotherapy with regard to the quality of life of palliative patients].

Heidemarie Seemann1,2, Johannes G Meran3.   

Abstract

I am reporting on a 74-year-old female patient with primary pulmonary and hepatic metastatic colon cancer. In the course of three-and-a-half years the patient decided to receive multiple cycles of palliative chemotherapy, irradiation of the liver and of the upper body. As a result of the extended anti-tumour therapy, remissions of the advanced cancer disease could be achieved repeatedly, which lead to a substantial increase of the patient's quality of life. This case shows that even in an advanced palliative situation the goal of a multimodal treatment is to curb disease progression and to extend the life and increase quality of life of the patient.

Entities:  

Mesh:

Year:  2010        PMID: 20300921     DOI: 10.1007/s10354-010-0752-y

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  21 in total

Review 1.  Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.

Authors:  Bruce J Giantonio
Journal:  Semin Oncol       Date:  2006-10       Impact factor: 4.929

2.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Authors:  Alfredo Falcone; Sergio Ricci; Isa Brunetti; Elisabetta Pfanner; Giacomo Allegrini; Cecilia Barbara; Lucio Crinò; Giovanni Benedetti; Walter Evangelista; Laura Fanchini; Enrico Cortesi; Vincenzo Picone; Stefano Vitello; Silvana Chiara; Cristina Granetto; Gianfranco Porcile; Luisa Fioretto; Cinzia Orlandini; Michele Andreuccetti; Gianluca Masi
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

Review 3.  Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.

Authors:  Mei Wu; Anastasia Rivkin; Trinh Pham
Journal:  Clin Ther       Date:  2008-01       Impact factor: 3.393

4.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

5.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 6.  New concepts in the therapeutic options of liver metastases from colorectal cancer.

Authors:  N Andromanakos; D Filippou; V Papadopoulos; G Kouraklis; E Christianakis; A Kostakis
Journal:  J BUON       Date:  2007 Oct-Dec       Impact factor: 2.533

7.  Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

Authors:  Byung Woog Kang; Tae Won Kim; Jae-Lyun Lee; Min-Hee Ryu; Heung Moon Chang; Chang Sik Yu; Jin Cheon Kim; Jong Hoon Kim; Yoon-Koo Kang; Jung Shin Lee
Journal:  Med Oncol       Date:  2008-05-22       Impact factor: 3.064

8.  An update and our experience with metastatic liver disease.

Authors:  Mahim Koshariya; Rajan B Jagad; Jun Kawamoto; P Papastratis; H Kefalourous; T Porfiris; Christina Tzouma; N J Lygidakis
Journal:  Hepatogastroenterology       Date:  2007-12

Review 9.  Managing liver metastases with conformal radiation therapy.

Authors:  Erkan Topkan; Huseyin Cem Onal; Melek Nur Yavuz
Journal:  J Support Oncol       Date:  2008-01

Review 10.  Radiotherapy of liver malignancies. From whole liver irradiation to stereotactic hypofractionated radiotherapy.

Authors:  Carlo Greco; Gianpiero Catalano; Alfio Di Grazia; Roberto Orecchia
Journal:  Tumori       Date:  2004 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.